Date: 2013-06-25
Type of information: R&D agreement
Compound: diagnostic markers
Company: Translational Genomics Research Institute (TGen) (USA) Ventana Medical Systems (USA), a member of the Roche Group (Switzerland)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease: pancreatic cancer
Details: * On June 25, 2013, the Translational Genomics Research Institute (TGen) and Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, have announced a collaborative research agreement to discover and develop diagnostic markers for treating cancer. The first project under the umbrella research agreement will focus on diagnostic, prognostic and drug biomarkers for pancreatic cancer.
Financial terms:
Latest news:
